Vital Signs - Perspectives in Oncology Drug Delivery

Vital Signs - Perspectives in Oncology Drug Delivery

 

RELEASE DATE
18-Jan-2010
REGION
North America
Research Code: 9561-00-9E-00-00
SKU: HC00587-NA-MR_04060
AvailableYesPDF Download

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
HC00587-NA-MR_04060

$1,500.00

$1,125.00save 25 %

DownloadLink
ENQUIRE NOW

Description

This issue of Vital Signs, released on January 18, 2010, provides a strategic overview of trends in MD, nurse and cancer patient feedback about drug delivery and treatment in oncology, as well as the value sought from this area from multiple facets of the pharma industry. Additionally, a company spotlight is provided for Cure DM, a biopharmaceutical company established to develop new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin therapy. Reimbursement and regulatory news from the FDA is also provided for the week of December 28, 2009.

Table of Contents

This week's issue:

Related Research
This issue of Vital Signs, released on January 18, 2010, provides a strategic overview of trends in MD, nurse and cancer patient feedback about drug delivery and treatment in oncology, as well as the value sought from this area from multiple facets of the pharma industry. Additionally, a company spotlight is provided for Cure DM, a biopharmaceutical company established to develop new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin therapy. Reimbursement and regulatory news from the FDA is also provided for the week of December 28, 2009.
More Information
No Index Yes
Podcast No
Industries Healthcare
WIP Number 9561-00-9E-00-00
Is Prebook No